Brief: Medicinova Announces Completion Of Enrollment In The Mid-Stage Clinical Trial Of Alcohol Use Disorder Drug
30/01/2023 23:28
Jan 30 (Reuters) - MediciNova Inc MNOV.O :
* MEDICINOVA ANNOUNCES COMPLETION OF ENROLLMENT IN THE PHASE
2B
CLINICAL TRIAL OF MN 166 (IBUDILAST) IN ALCOHOL USE DISORDER
Source text for Eikon: ID:nGNX4sVGks
Further company coverage: MNOV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicinova
See all newsBrief: 3D Investment Partners Cuts Stake In Medicinova To 9.88% From 11.22%, Filing Shows
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX
MediciNova falls as fatty liver drug misses significance on blood-fat reduction
US STOCKS ON THE MOVE-WhiteHawk, Nvidia, Snowflake